CoChat

Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Tauopathies are clinicopathological entities with increased and pathological deposition in glia and/or neurons of hyperphosphorylated aggregates of the microtubule-binding protein tau. In secondary tauopathies, i.e. Alzheimer's disease (AD), tau deposition can be observed, but tau coexists with another protein (amyloid-β). In the last 20 years, little progress has been made in developing disease-modifying drugs for primary and secondary tauopathies and available symptomatic drugs have limited efficacy. AREAS COVERED: The present review summarized recent advances about the development and challenges in treatments for primary and secondary tauopathies, with a focus on passive tau-based immunotherapy. EXPERT OPINION: Several tau-targeted passive immunotherapeutics are in development for treating tauopathies. At present, 14 anti-tau antibodies have entered clinical trials, and 9 of them are still in clinical testing for progressive supranuclear palsy syndrome and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, APNmAb005, MK-2214, PNT00, and PRX005). However, none of these nine agents have reached Phase III. The most advanced anti-tau monoclonal antibody for treating AD is semorinemab, while bepranemab is the only anti-tau monoclonal antibody still in clinical testing for treating progressive supranuclear palsy syndrome. Further evidence on passive immunotherapeutics for treating primary and secondary tauopathies will come from ongoing Phase I/II trials.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2023.2233892

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 82 references

Research works printed but not linked: 1

  1. Eli Lilly press release. https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional

Cited by

See all 23

Metadata

Authors
Panza, F., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Cirillo, N., Damiani, C., Altamura, M., Bellomo, A., Daniele, A., Solfrizzi, V., & Lozupone, M.
Affiliations
  • Gastroenterology Hospital "Saverio de Bellis" (IT)
  • Academic Center for Dentistry Amsterdam (NL)
  • University of Bari Aldo Moro (IT)
  • University of Foggia (IT)
  • Università Cattolica del Sacro Cuore (IT)
Corresponding author
Panza, Francesco
Venue
Expert Opinion on Investigational Drugs
Published
2023-07-03
Volume
32
Issue
7
Pages
625-634
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4383186645
Cited by
22
References
82
Citations by year
2026: 3 · 2025: 13 · 2024: 5 · 2023: 1
FWCI
0.79
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • VU Research Portal (submittedVersion)
Funders
Ministry of Health
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tauopathy, passive immunotherapy, tau aggregation, Alzheimer's disease, progressive supranuclear palsy, disease-modifying drugs, clinical trials, amyloid-beta
MeSH terms
Alzheimer Disease, Antibodies, Monoclonal, Humans, Immunotherapy, Supranuclear Palsy, Progressive, tau Proteins, Tauopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. https://app.cochat.ai/papers/10.1080/13543784.2023.2233892
The paper
Panza, F., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Cirillo, N., Damiani, C., Altamura, M., Bellomo, A., Daniele, A., Solfrizzi, V., & Lozupone, M. (2023). Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2023.2233892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.